Evidence map›Paper›PMID 41931627›Full record

ArticleScience advances2026

Hemostatic B-knob-triggered microgels (BK-TriGs) to address bleeding in neonates.

Nooshin Zandi, Kimberly Nellenbach, Connor Moore, Julia Storch, Sara R Abrahams, Matthew J Flick, Michael Daniele, Ashley Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nooshin ZandiLampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, Chapel Hill, NC, USA.ORCID 0009-0001-0403-3630
Kimberly NellenbachLampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, Chapel Hill, NC, USA.ORCID 0000-0002-7291-6750
Connor MooreLampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, Chapel Hill, NC, USA.ORCID 0009-0006-4776-0324
Julia StorchDepartment of Chemistry, North Carolina State University, Raleigh, NC, USA.ORCID 0009-0000-9681-1569
Sara R AbrahamsDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0009-0003-3079-8607
Matthew J FlickDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-5034-3162
Michael DanieleLampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, Chapel Hill, NC, USA.ORCID 0000-0002-2016-4091
Ashley BrownLampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill/North Carolina State University, Chapel Hill, NC, USA.ORCID 0000-0001-6995-1785

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemostatic immaturity in neonates presents critical challenges, especially during surgery, where bleeding and thrombosis risks are elevated. Current treatments rely on transfusing adult blood products, which may cause complications resulting from structural and functional differences between neonatal and adult fibrinogen. To address this, we developed hemostatic B-knob-triggered microgels (BK-TriGs) that target and bridge fibrinogen hole b sites. Functionalized with a fibrin hole b-specific peptide, BK-TriGs enhance clot density and resistance to degradation. In vitro studies using neonatal platelet-poor plasma (PPP) showed that at an optimal concentration, BK-TriGs increased clot density by more than 100% and improved stability by reducing fibrinolysis. Under flow conditions, BK-TriGs promoted robust clot formation compared to plasma-only controls. In an in vivo fib-null (Fga-/-) mouse model transfused with neonatal fibrinogen, BK-TriGs reduced blood loss by 50 to 60% and enhanced fibrin deposition at wound sites. This targeted approach offers a safer, more effective hemostatic solution tailored to neonatal clotting needs.

Indexed as

FibrinogenHemorrhageHemostaticsMicrogelsAnimalsAnimals, NewbornBlood CoagulationFibrinHemostasisHumansInfant, NewbornMiceFibrinFibrinogenHemostaticsMicrogels

Identifiers

PMID41931627
PMCPMC13048243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.